Updates are available Correction dated 2024-07-09

Article History

Received: 23 June 2023

Accepted: 28 March 2024

First Online: 25 April 2024

Change Date: 9 July 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41523-024-00666-y

Competing interests

: S.A.H. has contracted research with Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, and Phoenix Molecular Designs; and stock options with NK Max. A.B. received grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, and Immunomedics; grants and personal fees from Biotheranostics; and personal fees from Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Sankyo Pharma/AstraZeneca, Puma, Phillips, Eli Lilly, and Foundation Medicine. K.P. received honoraria for consultancy/advisory board functions and speaker fees from AstraZeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead Sciences, MSD, Novartis, Roche, and Seagen; support for attending meetings and/or travel from AstraZeneca, Novartis, Pfizer, PharmaMar, and Roche; and equipment, materials, drugs, medical writing, gifts or other services from MSD and Gilead Sciences. He has participated on a Data Safety Monitoring Board or Advisory Board of Eli Lilly, Gilead Sciences, MSD, Novartis, Pierre Fabre, Roche, Teva, and Vifor Pharma; is a board member of the Belgian Society of Medical Oncology; and is a member of the ESMO Young Oncologists Committee and the ESMO Resilience Task Force committee. His institution has received research grants from or had contracts with Sanofi and MSD; consulting fees from AstraZeneca, Gilead Sciences, MSD, Novartis, Pfizer, and Roche; and payment or honoraria from AstraZeneca, Eli Lilly, Gilead Sciences, MSD, Mundi Pharma, Novartis, Pfizer, and Roche. K.K. received contracts from Incyte, Novartis, Genentech, Lilly, Pfizer, Calithera, Immunomedics, Acetylon, Seattle Genetics, Amgen, Zeno, and CytomX; consulting fees from Lilly, Pfizer, Novartis, Eisai, AstraZeneca, Genentech, Immunomedics, Merck, Seattle Genetics, Cyclacel, and OncoSec Medical; payment/honoraria from Lilly; and support for attending meetings and/or travel from Lilly, AstraZeneca, and Pfizer. He is a member of steering committees at Immunomedics, AstraZeneca, and Genentech. His other financial/non-financial interests include having a spouse who has employment with Grail, Array, and Pfizer. L.A.C. participated on a Data Safety Monitoring Board or Advisory Board of Sanofi Aventis, Novartis, Genentech/Roche, GSK, AstraZeneca/Daiichi Sankyo, and Aptitude Health. Her other financial or non-financial interests include having a spouse who has served on the board of Falcon Therapeutics and who has had involvement in a neural stem cell therapy patent. H.S.R. received grants from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi Sankyo, Seattle Genetics, Eisai, MacroGenics, Sermonix, Immunomedics, and AstraZeneca; non-financial support from Daiichi Sankyo, Mylan, Pfizer, Merck, Novartis, AstraZeneca, and MacroGenics; and personal fees from Mylan, Puma, and Samsung. A.B. reports grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, and Immunomedics; grants and personal fees from Biotheranostics; and personal fees from Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Sankyo Pharma/AstraZeneca, Puma, Phillips, Eli Lilly, and Foundation Medicine. V.D. received honoraria from and consulting/advisory roles with Daiichi Sankyo, Gilead Sciences, MSD, Pierre Fabre Oncologie, Roche/Genentech, Novartis, Lilly, Pfizer, AstraZeneca, Eisai, AbbVie, and Seagen; and participated in speakers’ bureaus and support for travel, accommodation, and expenses from Gilead, Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, and Seagen. S.P. has stock/stock options from Gilead as an employee. R.D. has stock/stock options from Gilead as an employee. Y.Z. has stock/stock options from Gilead as an employee. S.M.T. reports grants and personal fees from Immunomedics/Gilead, AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Exelixis, Bristol Myers Squibb, Eisai, NanoString, Sanofi, Odonate, and Immunomedics/Gilead; personal fees from Puma, Celldex, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, AbbVie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi Sankyo, CytomX, Samsung Bioepis Inc., Certara, Mersana Therapeutics; and grants from Cyclacel.